Slayback Garners $50m Investment From Everstone

Backing For Complex Generics Firm Follows KKR’s $60m In 2016

 
• By Dave Wallace

Slayback Pharma and the Everstone Group have struck a deal that will see Everstone invest up to $50m in the US-based complex generics specialist.

Watch_Investment
Everstone has agreed to invest up to $50m in Slayback • Source: Shutterstock

More from Deals

More from Business